- <![CDATA[Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss]]><![CDATA[How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.]]>onclive · 2mo ago↗ source
- Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacyHere we go again? Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but slowed patients’ clinical decline…Endpoints · 2mo ago↗ source
- Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approvalRegenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027. The biotech hopes to be the second company to c…